NEUPHORIA THERAPEUTICS INC (NEUP) Stock Overview
NASDAQ:NEUP - US64136E1029 - Common Stock
NEUP Key Statistics, Chart & Performance
The current stock price of NEUP is 13.92 USD. In the past month the price increased by 89.14%.
NEUP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.98 | 373.87B | ||
| AMGN | AMGEN INC | 12.77 | 149.94B | ||
| GILD | GILEAD SCIENCES INC | 14.89 | 143.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.94 | 99.62B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 61.52B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.18 | 58.91B | ||
| ARGX | ARGENX SE - ADR | 82.3 | 46.69B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.49 | 37.32B | ||
| INSM | INSMED INC | N/A | 30.85B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.28B | ||
| NTRA | NATERA INC | N/A | 23.30B | ||
| BIIB | BIOGEN INC | 8.91 | 20.91B |
Related stock screener links
About NEUP
Company Profile
Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is headquartered in Burlington, Massachusetts and currently employs 8 full-time employees. Its lead drug candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute, as-needed treatment of social anxiety disorder and for the chronic treatment of post-traumatic stress disorder. BNC210 is a well-tolerated, broad-spectrum antianxiety experimental therapeutic, designed to restore neurotransmitter balance in relevant brain areas, providing rapid relief from stress and anxiety symptoms without the common pitfalls of sedation, cognitive impairment, or addiction. In addition, the Company has two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions.
Company Info
NEUPHORIA THERAPEUTICS INC
100 Summit Dr
Burlington MASSACHUSETTS US
Employees: 8
NEUPHORIA THERAPEUTICS INC / NEUP FAQ
What is the stock price of NEUPHORIA THERAPEUTICS INC today?
The current stock price of NEUP is 13.92 USD. The price decreased by -7.78% in the last trading session.
What is the ticker symbol for NEUPHORIA THERAPEUTICS INC stock?
The exchange symbol of NEUPHORIA THERAPEUTICS INC is NEUP and it is listed on the Nasdaq exchange.
On which exchange is NEUP stock listed?
NEUP stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for NEUPHORIA THERAPEUTICS INC stock?
7 analysts have analysed NEUP and the average price target is 21.42 USD. This implies a price increase of 53.88% is expected in the next year compared to the current price of 13.92. Check the NEUPHORIA THERAPEUTICS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is NEUPHORIA THERAPEUTICS INC worth?
NEUPHORIA THERAPEUTICS INC (NEUP) has a market capitalization of 26.17M USD. This makes NEUP a Nano Cap stock.
How many employees does NEUPHORIA THERAPEUTICS INC have?
NEUPHORIA THERAPEUTICS INC (NEUP) currently has 8 employees.
What are the support and resistance levels for NEUPHORIA THERAPEUTICS INC (NEUP) stock?
NEUPHORIA THERAPEUTICS INC (NEUP) has a support level at 7.66. Check the full technical report for a detailed analysis of NEUP support and resistance levels.
Is NEUPHORIA THERAPEUTICS INC (NEUP) expected to grow?
The Revenue of NEUPHORIA THERAPEUTICS INC (NEUP) is expected to decline by -71.13% in the next year. Check the estimates tab for more information on the NEUP EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy NEUPHORIA THERAPEUTICS INC (NEUP) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of NEUP, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of NEUP, evaluating the profitability, health, valuation and growth aspects
- NEUPHORIA THERAPEUTICS INC (NEUP) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- NEUPHORIA THERAPEUTICS INC (NEUP) Sales and EPS estimates to see what analysts future expectations are.
- NEUPHORIA THERAPEUTICS INC (NEUP) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- NEUPHORIA THERAPEUTICS INC (NEUP) Insider and Institutional Ownership to learn about the owners and their transactions.
- NEUPHORIA THERAPEUTICS INC (NEUP) Stock Chart to make your own analysis
- NEUPHORIA THERAPEUTICS INC (NEUP) Latest news and press-releases to stay up to date.
Does NEUPHORIA THERAPEUTICS INC (NEUP) stock pay dividends?
NEUP does not pay a dividend.
What is the Price/Earnings (PE) ratio of NEUPHORIA THERAPEUTICS INC (NEUP)?
The PE ratio for NEUPHORIA THERAPEUTICS INC (NEUP) is 2.67. This is based on the reported non-GAAP earnings per share of 5.21 and the current share price of 13.92 USD. Check the full fundamental report for a full analysis of the valuation metrics for NEUP.
What is the Short Interest ratio of NEUPHORIA THERAPEUTICS INC (NEUP) stock?
The outstanding short interest for NEUPHORIA THERAPEUTICS INC (NEUP) is 0.63% of its float. Check the ownership tab for more information on the NEUP short interest.
NEUP Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to NEUP.
NEUP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to NEUP. NEUP may be in some trouble as it scores bad on both profitability and health.
NEUP Financial Highlights
Over the last trailing twelve months NEUP reported a non-GAAP Earnings per Share(EPS) of 5.21. The EPS decreased by -109.17% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -25.24% | ||
| ROE | -39.9% | ||
| Debt/Equity | 0 |
NEUP Forecast & Estimates
7 analysts have analysed NEUP and the average price target is 21.42 USD. This implies a price increase of 53.88% is expected in the next year compared to the current price of 13.92.
For the next year, analysts expect an EPS growth of 94.49% and a revenue growth -71.13% for NEUP